What are the risks for a 75-year-old man receiving supratherapeutic testosterone therapy who has polycythemia and significant albuminuria?

Immediate Risk Assessment and Management

This 75-year-old man on supratherapeutic testosterone with polycythemia and significant albuminuria faces substantially elevated cardiovascular and thrombotic risk that requires urgent intervention—the testosterone dose must be reduced or discontinued immediately, and therapeutic phlebotomy should be strongly considered.

Critical Risk Factors Present

This patient presents with a dangerous triad:

1. Polycythemia from supratherapeutic testosterone: Elevated hematocrit increases blood viscosity, which can aggravate vascular disease in coronary, cerebrovascular, and peripheral circulations—particularly dangerous in elderly patients 1.

2. Advanced age (75 years): The risk of hemoconcentration complications is particularly grave in the elderly due to pre-existing vascular disease 1.

3. Significant albuminuria (UACR 96 mg/g): This indicates underlying kidney disease and likely represents systemic vascular pathology, compounding cardiovascular risk.

Specific Cardiovascular and Thrombotic Risks

Polycythemia-Related Thrombotic Risk

Men who develop polycythemia (hematocrit ≥52%) while on testosterone therapy have a 35% increased risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) in the first year (OR 1.35,95% CI 1.13-1.61, p <0.001) 2. This represents:

• Myocardial infarction
• Stroke
• Peripheral vascular thrombosis
• Deep venous thrombosis
• Pulmonary embolism

The incidence of erythrocytosis varies dramatically by testosterone formulation—intramuscular injections cause polycythemia in up to 43.8% of patients, compared to 15.4% with transdermal preparations 1. If this patient is receiving injectable testosterone, the risk is substantially higher.

Renal Implications

The elevated urine albumin/creatinine ratio of 96 mg/g indicates:

• Moderately increased albuminuria (30-300 mg/g range)
• Underlying chronic kidney disease
• Increased cardiovascular disease risk independent of testosterone therapy
• Potential for worsening renal function with hyperviscosity and reduced renal perfusion

The combination of polycythemia-induced hyperviscosity with pre-existing renal microvascular disease creates a particularly high-risk scenario for acute kidney injury and progressive nephropathy.

Immediate Management Algorithm

Step 1: Assess Current Hematocrit Level

• If hematocrit ≥54%: This represents severe erythrocytosis—stop testosterone immediately and arrange urgent therapeutic phlebotomy 1
• If hematocrit 52-54%: Withhold testosterone and consider therapeutic phlebotomy 1
• If hematocrit <52% but rising: Reduce testosterone dose by at least 50% and switch to transdermal formulation if currently using injections

Step 2: Address Supratherapeutic Dosing

Since the patient is on supratherapeutic testosterone:

• Supraphysiologic testosterone levels directly correlate with erythrocytosis incidence—higher doses cause proportionally more polycythemia 1
• Dose reduction is mandatory regardless of hematocrit level
• Target physiologic testosterone levels (300-1000 ng/dL), not supraphysiologic levels

Step 3: Formulation Optimization

Switch from injectable to transdermal testosterone if currently using injections:

• Injectable testosterone enanthate causes erythrocytosis in 43.8% vs 15.4% with transdermal patches 1
• Transdermal gel (5 mg/day) causes erythrocytosis in only 2.8% of patients 1
• This single change can dramatically reduce hematocrit 3

Step 4: Monitoring Protocol

• Check hematocrit every 2-4 weeks until stable below 52% 1
• Monitor renal function (creatinine, eGFR) and UACR monthly initially
• Assess for symptoms of hyperviscosity: headache, visual changes, chest pain, dyspnea

Critical Caveats and Pitfalls

The Phlebotomy Controversy

While guidelines recommend therapeutic phlebotomy for elevated hematocrit 1, recent evidence questions its safety:

• Phlebotomy lowers tissue oxygen and depletes iron stores, potentially triggering pathways that increase thrombotic risk 4
• No evidence supports efficacy or safety of therapeutic phlebotomy specifically for testosterone-induced erythrocytosis 4
• Shared decision-making is essential before initiating phlebotomy 4

Practical approach: Prioritize testosterone dose reduction and formulation change first. Reserve phlebotomy for hematocrit ≥54% or symptomatic hyperviscosity.

Cardiovascular Disease Considerations

The evidence on testosterone and cardiovascular risk is mixed:

• Some data suggest testosterone may have neutral or beneficial cardiovascular effects at physiologic doses 1
• However, one trial in older men with mobility limitations and high chronic disease burden showed increased cardiovascular events with testosterone (23 events vs 5 in placebo group) 5
• This patient's profile (age 75, albuminuria suggesting vascular disease) resembles the high-risk population in that terminated trial 5

Renal-Specific Concerns

The albuminuria adds complexity:

• Testosterone can cause fluid retention, potentially worsening hypertension and kidney function 1
• Hyperviscosity from polycythemia reduces renal blood flow, risking acute-on-chronic kidney injury
• Monitor blood pressure closely—uncontrolled hypertension with albuminuria accelerates renal decline

Risk Stratification Summary

Highest mortality/morbidity risks in this patient:

1. Acute thrombotic events (MI, stroke, PE/DVT)—risk increased 35% with polycythemia on testosterone 2
2. Progressive renal failure—hyperviscosity plus existing albuminuria
3. Cardiovascular decompensation—elderly patient with likely underlying vascular disease 5

The supratherapeutic dosing is the modifiable factor that must be addressed immediately 1. The FDA label explicitly warns about polycythemia risk and states hemoglobin/hematocrit should be checked periodically with appropriate measures instituted if erythrocytosis develops 6.

Quality of Life Considerations

Stopping or reducing testosterone may cause:

• Return of hypogonadal symptoms (fatigue, decreased libido, mood changes)
• Loss of muscle mass and strength gains

However, these quality of life concerns are vastly outweighed by the mortality risk from stroke, MI, or PE in this high-risk patient. The goal is to find the lowest effective testosterone dose using the safest formulation (transdermal) that maintains hematocrit <52% 1, 3.